|Systematic (IUPAC) name|
|Biological half-life||16 h|
|CAS Registry Number|
|Molecular mass||396.46 g/mol
494.46 g/mol (phosphate)
Toceranib is a receptor tyrosine kinase inhibitor and is used in the treatment of canine mast cell tumor also called mastocytoma. Together with masitinib (Kinavet (US)/Masivet (EU/ROW) by AB Science), toceranib is the only dog-specific anti-cancer drug approved by the U.S. Food and Drug Administration. It is marketed as Palladia as its phosphate salt, toceranib phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.
- London CA, Malpas PB, Wood-Follis SL, et al. (June 2009). "Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision.". Clin Cancer Res 15 (11): 3856–65. doi:10.1158/1078-0432.CCR-08-1860. PMID 19470739.
- CBS News FDA Approves First-Ever Dog Cancer Drug
- FDA NEWS RELEASE
- In Trials for New Cancer Drugs, Family Pets Are Benefiting, Too, New York Times
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|